Iridex Corporation logo

Iridex Corporation (IRIX)

Market Open
16 Jun, 19:38
NASDAQ (CM) NASDAQ (CM)
$
1. 19
+0.01
+0.8475%
$
19.5M Market Cap
- P/E Ratio
- Div Yield
55,388 Volume
-0.37 Eps
$ 1.18
Previous Close
Add Transaction
Day Range
1.17 1.19
Year Range
0.87 1.65
Want to track IRIX and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!

Summary

IRIX trading today higher at $1.19, an increase of 0.8475% from yesterday's close, completing a monthly increase of 14.4231% or $0.15. Over the past 12 months, IRIX stock gained 5.3097%.
IRIX is not paying dividends to its shareholders.
The last earnings report, released on May 11, 2026, exceeded the consensus estimates by 0%. On average, the company has surpassed earnings expectations by 0.0133%, based on the last three reports.
The stock of the company had never split.
The company's stock is traded on one exchange.

IRIX Chart

People also search for

SkyAI, Inc. Common Stock
$ 1.25
-0.4%
PXS
Pyxis Tankers Inc.
$ 4.49
-0.1911%
Globus Maritime Ltd.
$ 2.6
-5.1095%
Rising Dragon Acquisition Corp.
$ 6.01
-5.205%
Pioneer Power Solutions Inc.
$ 4.41
+3.1616%
IRIX Stock Up 4% As Q1 Loss Narrows Y/Y on Glaucoma Product Growth

IRIX Stock Up 4% As Q1 Loss Narrows Y/Y on Glaucoma Product Growth

IRIDEX posts a narrower year-over-year net loss per share in Q1'26 as strong glaucoma product sales and lower operating costs helped offset weakness in retina sales and supply-chain disruptions.

Zacks | 3 weeks ago
IRIDEX Corporation (IRIX) Q1 2026 Earnings Call Transcript

IRIDEX Corporation (IRIX) Q1 2026 Earnings Call Transcript

IRIDEX Corporation (IRIX) Q1 2026 Earnings Call Transcript

Seekingalpha | 3 weeks ago
Iridex's Q4 Loss Narrows Year Over Year on Retina Sales Growth

Iridex's Q4 Loss Narrows Year Over Year on Retina Sales Growth

IRIX incurs narrower year-over-year loss per share in Q4 as growth in retina systems and glaucoma probes boosts revenues, though margins remain pressured by higher costs.

Zacks | 2 months ago

Iridex Corporation (IRIX) FAQ

What is the stock price today?

The current price is $1.19.

On which exchange is it traded?

Iridex Corporation is listed on NASDAQ (CM).

What is its stock symbol?

The ticker symbol is IRIX.

Does it pay dividends? What is the current yield?

It does not pay dividends to its shareholders.

What is its market cap?

As of today, the market cap is 19.5M.

Has Iridex Corporation ever had a stock split?

No, there has never been a stock split.

Iridex Corporation Profile

Electrical Equipment Industry
Industrials Sector
Patrick Mercer CEO
NASDAQ (CM) Exchange
462684101 CUSIP
US Country
93 Employees
- Last Dividend
- Last Split
15 Feb 1996 IPO Date

Overview

IRIDEX Corporation is an ophthalmic medical technology company at the forefront of developing and providing innovative laser systems, delivery devices, and consumable instrumentation designed to treat sight-threatening eye diseases in the field of ophthalmology. With its roots going back to 1989 and originally known as IRIS Medical Instruments, Inc., the company underwent a name change to IRIDEX Corporation in November 1995. From its headquarters in Mountain View, California, IRIDEX has committed itself to serve ophthalmologists, research and teaching hospitals, government installations, surgical centers, veterinary practices, and office clinics both in the United States and internationally. Products are marketed directly as well as through a network of independent distributors worldwide, demonstrating their global reach and commitment to addressing eye health.

Products and Services

IRIDEX Corporation offers a wide range of high-quality ophthalmic laser systems and accessories designed for various treatments. Here are some of their key products and services:

  • Cyclo G6 Laser System: Designed for the treatment of glaucoma, this system represents a pivotal advancement in managing a condition that can lead to severe vision impairment or blindness.
  • IQ 532 and IQ 577 Laser Systems: These systems are utilized for the treatment of retinal disorders, providing precise and effective therapy options for patients suffering from conditions like diabetic retinopathy.
  • OcuLight Laser Photocoagulation Systems (TX, SL, SLx, GL, GLx): A series of lasers used to treat a range of issues including proliferative diabetic retinopathy, macular holes, retinal tears, and detachments, offering versatile solutions in the management of retinal diseases.
  • TxCell Scanning Laser Delivery System: This device enables physicians to perform multi-spot pattern scanning, enhancing the efficiency and coverage of laser treatments.
  • Slit Lamp Adapter: Allows the integration of a standard slit lamp with laser systems for diagnostic and treatment procedures, thereby expanding the utility of existing equipment in clinics and hospitals.
  • Laser Indirect Ophthalmoscope: Facilitates procedures to treat peripheral retinal disorders, ensuring comprehensive care for patients with complex retinal conditions.
  • MicroPulse P3 Probe: Used with the Cyclo G6 system, this probe allows for MicroPulse transscleral laser therapy, a tissue-sparing option for treating glaucoma.
  • G-Probe and G-Probe Illuminate: These probes are essential for procedures aimed at treating uncontrolled and refractory glaucoma, showcasing IRIDEX's commitment to innovative glaucoma management solutions.
  • EndoProbe Family of Products: Designed for use in vitrectomy procedures, these products highlight IRIDEX's contribution to advanced surgical options for eye diseases.

IRIDEX's commitment to innovation is evident in their comprehensive range of products and services designed to meet the needs of ophthalmologists and their patients globally.

Contact Information

Address: 1212 Terra Bella Avenue
Phone: 650 940 4700